Thursday, 17 Aug 2017

You are here

Actemra - First FDA Approved Drug for Giant Cell Arteritis

Genentech announced on May 22 that subcutaneous (sc) tocilizumab (TCZ) was granted FDA approval for Giant Cell Arteritis (GCA) – also known as temporal arteritis.

TCZ was shown to be effective in the landmark GiACTA study presented at the Annual ACR meeting in November 2016. The FDA gave the drug Breakthrough Therapy Designation In October 2016 and granted a priority review for this indication in January 2017.

Actemra (IV and sc) is currently approved for use in moderate to severely active rheumatoid arthritis. The IV formulation iwas also FDA approved for use in polyarticular juvenile idiopathic arthritis (JIA) and systemic JIA (over age 2 yrs.). The approval of sc TCZ for GCA becomes the sixth FDA approval for TCZ since its initial approval in 2010.

The new indication for GCA is based on the phase III GiACTA study that demonstrated that TCZ with steroids was superior to steroid therapy alone.  GiACTA was a 52-week, Phase randomized, double-blind, placebo-controlled trial that included 251 patients, from 14 countries, with either newly diagnosed or relapsing GCA.  All patients received initial prednisone (that was tapered over 26 or 52 weeks); half were on placebo and the other half received TCZ 162 mg (either weekly or every other week) in addition to prednisone. The primary endpoint was sustained remission from week 12 to week 52.

Patients treated with TCZ had sustained remission in 56 % of patients receiving weekly TCZ and 53% receiving every-other week dosing (compared to 18% of placebo treated patients at 52 weeks). Time to first flare following clinical remission was significantly later in both TCZ treated groups compared to placebo. Impressively, 56% of TCZ patients were in steroid-free disease remission at one year, compared to 14% for those on steroid only taper regimen. 

Thus TCZ had a significant steroid-sparing effect in this study.  No new safety signals were observed at the time of this analysis. Adverse events were similar to those seen in previous TCZ developmental clinical studies. The rate is serious infections in GiACTA was events was 9.7 per 100 patient years in the Actemra weekly group and 4.4 per 100 patient years in the every other week Actemra group. There were no bowel perforations noted in the trial.

GiACTA is a 3 year study and the open-label portion is ongoing.

The package insert ( states that sc TCZ is indicated for use in adult patients with GCA.  The recommended dosing is 162 mg given once weekly as a subcutaneous injection, in combination with a tapering course of glucocorticoids.  Every other week (162 mg dose) may be prescribed based on clinical considerations. The use of TCZ in GCA comes with the same warnings and precautions seen with other (e.g., RA) indications, including warnings about serious infections, GI perforations, the need for monitoring neutrophil counts, hepatic enzymes and lipids.  Patients should be screened for TB infection and live vaccines should be avoided with TCZ. 


The author has received compensation as an advisor or consultant on this subject

Rheumatologists' Comments

Just got detailed by pharma about actemra for GCA. Only problem is it is subq so because most patients with GCA are on Medicare it is not covered by part B which it would have been if they had gotten approval for IV actemra which also works for GCA. Since they will have to use part D it will cost them more money than many of them have. Genentech says we can fill out paperwork to apply for patient assistance if it is available and they meet income qualifications. Filling out more paperwork which may or may not get them the drug is exactly what I want to do! Sterling West,MD

More Like This

Therapeutic Update: 5 Questions on Sirukumab FDA Hearing

Drs. Cush and Gibofsky answer 5 questions about the August 2, 2017 FDA Arthritis Advisory Committee meeting that reviewed the NDA for sirukumab use in rheumatoid arthritis. The panel voted against (1-12) the approval of sirukumab.

Arthritis Advisory Panel Votes Down Sirukumab

On Wednesday, August 2, the FDA convened the Arthritis Advisory Committee (AAC) to evaluate the safety and efficacy of Janssen’s anti-IL-6 monoclonal antibody, sirukumab. The panel included over 13 voting members that included adult and pediatric rheumatologists, statisticians, pharmacologists and patient representatives.

NEJM: Actemra Effective in Giant Cell Arteritis

On May 22, Genentech received FDA approval for the use of subcutaneous (sc) tocilizumab (TCZ) in patients with giant cell arteritis (GCA) – also known as temporal arteritis. This new indication is largely based on the landmark GiACTA study presented at the annual ACR meeting in November 2016. The results are now published in the New England Journal of Medicine (NEJM). 

Baricitinib Derailed by FDA Review

Eli Lilly and Co disclosed today that upon further discussions with the US Food and Drug Administration (FDA) there would be a delay in further regulatory decisions regarding baricitinib, a JAK inhibitor, that is being developed for use in rheumatoid arthritis (RA).  

Rheumatologists and Patients Concerns over Biosimilars - RheumNow “Live Vote” Results

The RheumNow “Live Vote” on the use, uptake and safety of biosimilars contrasts rheumatologist and patient views. Despite FDA approval and looming introduction, there is considerable concern, knowledge gaps and hesitancy regarding their uptake in the US. The survey's primary question demonstrates that less than one-third of US rheumatologists are prepared to adopt biosimilars when they are available.